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Since CXCL12 and its receptors, CXCR4 and CXCR7, have been found in the brain, the
role of this chemokine has been expanded from chemoattractant in the immune system to
neuromodulatory in the brain. Several pieces of evidence suggest that this chemokine
system could crosstalk with the GABAergic system, known to be the main inhibitory
neurotransmitter system in the brain. Indeed, GABA and CXCL12 as well as their receptors
are colocalized in many cell types including neurons and there are several examples in
which these two systems interact. Several mechanisms can be proposed to explain how
these systems interact, including receptor–receptor interactions, crosstalk at the level of
second messenger cascades, or direct pharmacological interactions, as GABA and GABAB
receptor agonists/antagonists have been shown to be allosteric modulators of CXCR4.The
interplay between CXCL12/CXCR4-CXCR7 and GABA/GABAA-GABAB receptors systems
could have many physiological implications in neurotransmission, cancer and inﬂammation.
In addition, the GABAB agonist baclofen is currently used in medicine to treat spasticity in
patients with spinal cord injury, cerebral palsy, traumatic brain injury, multiple sclerosis, and
other disorders. More recently it has also been used in the treatment of alcohol dependence
and withdrawal. The allosteric effects of this agent on CXCR4 could contribute to these
beneﬁcial effects or at the opposite, to its side effects.
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INTRODUCTION
The chemokine CXCL12/SDF1 has been found to play impor-
tant roles in several processes involved in ischemic stroke and its’
subsequent repair (Wang et al., 2012), brain tumor pathogenesis
(Rempel et al., 2000; Duda et al., 2011), human immunodeﬁciency
virus (HIV) encephalopathy (Li and Ransohoff, 2008), Multi-
ple Sclerosis and stem cell migration (Carbajal et al., 2010). This
chemokine of 67 amino-acids was ﬁrst believed to act on a single
receptor, the CXCR4. Since then, a second receptor has been found
to be another target of CXCL12, namely CXCR7 (Schonemeier
et al., 2008).
CXCR4 is a G protein-coupled receptor (GPCR) widely
expressed in a variety of cell types including leucocytes, where
it promotes migration, recruitment and activation (Bonavia et al.,
2003; Salcedo and Oppenheim, 2003; Juarez et al., 2004; Choi and
An, 2011; Comerford and McColl, 2011), neurons, where it mod-
ulates electrical activity (Banisadr et al., 2002; Guyon and Nahon,
2007; Rostene et al., 2011), and various cancers and metastases
(Wang et al., 2006) where it is involved in tumor progression (Liu
et al., 2006; Gao et al., 2010; Zhao et al., 2010). CXCR4 also binds
the HIV-1 viral envelope glycoprotein gp120 (Doranz et al., 1997;
Gabuzda and Wang, 2000). Thus CXCR4 is an important thera-
peutic target for stroke, inﬂammation, neuromodulation, cancer,
and in the prevention of HIV infection. CXCR4 couples to the
Gi family of proteins activating multiple G-protein dependent
pathways (Lazarini et al., 2003; Busillo and Benovic, 2007). In
neurons, CXCR4 stimulation has been shown to activate a G-
protein-coupled inward rectiﬁer K+ (GIRK), a voltage-gated K
channel Kv2.1 associated to neuronal survival, and to increase
high voltage activated (HVA) Ca2+ currents (Guyon and Nahon,
2007; Shepherd et al., 2012).
CXCR7, contrary to CXCR4, could not be demonstrated to be
coupled to G proteins. Despite its phylogenic relation and ligand
binding properties, CXCR7 does not mediate typical chemokine
receptor responses such as leukocyte trafﬁcking. It was ﬁrst
believed to bemainly involved in ligand sequestration (Thelen and
Thelen, 2008). However, recent studies show that ligand binding
to CXCR7 activates MAP kinases through Beta-arrestins (Zabel
et al., 2009; Rajagopal et al., 2010), and its functions could include
modulation of circadian glucocorticoid oscillation and emotional
behavior (Ikeda et al., 2013).
γ-aminobutyric acid (GABA) is the chief neuro-inhibitory
neurotransmitter in mammalian systems but it also plays impor-
tant roles in CNS development by regulating neurogenesis and
synaptogenesis (LoTurco et al., 1995; Somogyi et al., 1995). In
contrast to its inhibitory actions on adult neurons, GABA is
capable of depolarizing neuronal progenitor cells and immature
neurons (Ben-Ari, 2002; Rheims et al., 2008) and participates in
the formation of a primitive network-driven pattern of electri-
cal activity called giant depolarizing potentials (GDPs), which are
critical for the generation of large oscillations of intracellular cal-
cium, for activity-dependent modulation of neuronal growth and
synapse formation (Ben-Ari, 2002). HIV-1 gp120,whichbinds and
stimulates CXCR4, enhances GDPs in neonatal rat hippocampus
(Kasyanov et al., 2006), underlying the role played by CXCR4 in
the developmental process. Moreover, the developmental function
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of GABA is in part regulated byGABAproduction, a processmedi-
ated by glutamic acid decarboxylases (GADs), the key rate-limiting
enzymes for synthesis of GABA. Two GAD isoforms, GAD65, and
GAD67, are expressed in the adult nervous system (Erlander et al.,
1991). It has been shown that CXCL12/CXCR4 signaling induces
expression of GAD67 in embryonic hippocampal cultured neu-
rons via ERKs and the transcription factor Egr1, a mechanism
whichmay promote thematuration of GABAergic neurons during
development (Luo et al., 2008).
The GABA type A (GABAA) receptors are ionotropic recep-
tors. In response to binding GABA, their chloride-selective pore
open resulting in hyperpolarization of the neuron. This causes
an inhibitory effect on neurotransmission by diminishing the
chance of a successful action potential occurring. The protein
contains a number of different allosteric binding sites whichmod-
ulate the activity of the receptor indirectly and are the targets
of various other drugs, including the benzodiazepines, barbi-
turates, ethanol, neuroactive steroids, inhaled anesthetics, and
picrotoxin, among others (Olsen and Sieghart, 2009). GABAA
receptors are largely expressed in the nervous system but to
a limited extent they can be found in non-neuronal tissues
(Mohler et al., 1995).
Like chemokine receptors, GABAB receptors are GPCRs.
GABAB receptors are obligatory heterodimers with 2 homologous
subunits (GB1 and GB2) required for functioning (Bowery et al.,
1980), are widely expressed and distributed in the central nervous
system (Kaupmann et al., 1998) where they can activate the GIRK
channel, negatively modulate HVA Ca2+ channels and activate
diverse intracellular pathways (Guyon and Leresche, 1995; Laviv
et al., 2011). GABAB receptors are also expressed on cells of the
immune system with a possible link to the inﬂammatory response
(Tian et al., 2004; Rane et al., 2005). As a consequence, there is
a rich pharmacology aimed at targeting GABAB receptors, with
numerous compounds currently being used with the presump-
tion that they are highly selective for these receptors (Bowery,
1993; Froestl, 2010).
CO-LOCALIZATION OF CXCL12/CXCR4-CXCR7 AND
GABA/GABA RECEPTOR SYSTEMS
In the periphery, CXCR4 and GABA receptors are often colocal-
ized in the same cells. For example, in pathological conditions,
CXCR4 and GABAA receptors are both expressed in leuko-
cytes (Light et al., 2013) and CXCR4 and GABAB receptors are
both found in cells of the immune system with a possible link
to the inﬂammatory response (Tian et al., 2004; Rane et al.,
2005; Wang et al., 2008). In the brain, CXCL12 receptors have
been found to be expressed in several neuronal populations,
which all express also GABA receptors (Banisadr et al., 2002;
Schonemeier et al., 2008).
In the developing mouse CNS, expression of CXCR4 starts
as early as embryonic day 8.5 and is sustained until adulthood.
From E 15.5, both CXCR4 and CXCL12 are expressed in the cor-
tex, olfactory bulb, hippocampus, as well as the meninges and
endothelia. During postnatal development, CXCL12 inﬂuences
the migration of GABAergic interneurons in the cortex by acting
via CXCR4 (Stumm et al., 2003; Tiveron et al., 2006). In adults,
CXCR4 immunoreactivity has been reported in many brain areas
including cerebral cortex, caudate putamen, globus pallidus, sub-
stantia innominata, supraoptic, and paraventricular hypothalamic
nuclei, ventromedial thalamic nucleus and substantia nigra, and
in virtually all CNS cells including neurons, astrocytes, microglia,
ologidendrocytes, and endothelial cells (Banisadr et al., 2002).
CXCR7, at embryonic stages, is distributed in the germinative
zone of the ganglionic eminences, caudate putamen, and along
the routes of GABAergic precursors migrating toward the cor-
tex (Schonemeier et al., 2008). In the cortex, CXCR7 is expressed
in GABAergic precursors and in some reelin-expressing Cajal-
Retzius cells. Unlike CXCR4, CXCR7 is abundant in neurons
forming the cortical plate and sparse in the developing dentate
gyrus and cerebellar external germinal layer. CXCR7 is often co-
localized with GAD in the postnatal cortex, hippocampus and
cerebellum (Schonemeier et al., 2008). In the adult brain, CXCR7
is expressed by blood vessels, pyramidal cells in CA3, and mature
dentate gyrus granule cells, which is reminiscent of the SDF-1
pattern. Further neuronal structures expressing CXCR7 include
the olfactory bulb, accumbens shell, supraoptic and ventrome-
dial hypothalamic nuclei, medial thalamus, and brain stem motor
nuclei (Schonemeier et al., 2008).
Moreover, at the sub-cellular level, CXCL12 has partly a vesicu-
lar localization in axonal terminals (Reaux-Le Goazigo et al., 2012)
and CXCR4 receptors are mainly located on the neuronal plasma
membrane, where, like GABA receptors, they are present at pre-
synaptic and post-synaptic sites of central terminals (Reaux-Le
Goazigo et al., 2012).
Therefore, in the brain, the interactions between the two
systems are made possible by a high level of colocalization.
EXAMPLES OF INTERPLAY BETWEEN THE TWO SYSTEMS
CXCL12 and GABAergic agents have complementary function-
ality. Similarly to CXCL12, GABA, and GABAergic agents have
chemotaxic properties. For example, neutrophils (Rane et al.,
2005) but also stem/progenitor cells (Zangiacomi et al., 2009)
and embryonic neurons (Behar et al., 1996) and are attracted by
GABA. GABAergic agents have also been shown to have anti-
inﬂammatory properties45. The involvement of GABA receptors
has been proposed in these effects, but curiously, the putative
cross-talk between the two systems has been poorly investigated.
However, several groups have described the importance of the
interplay between CXCR4 and GABABreceptors. For example, we
and others have shown inhibition of CXCL12-induced migra-
tion of cancer cells by GABABligands (Wang et al., 2008; Guyon
et al., 2013). Recently, it has also been shown that CXCL12 and
GABA acting on its GABAA receptors interact to regulate axophilic
migration of GnRH neurons (Casoni et al., 2012). GABAergic
and CXCL12/CXCR4 systems interact, promoting linear rather
than random movement. The simultaneous activation of these
signaling pathways result in tight control of cellular speed and
improved directionality along the migratory pathway of GnRH
neurons (Casoni et al., 2012).
There is also evidence thatCXCL12 can interactwithGABA sys-
tems to modulate neurotransmission. Indeed, CXCL12 increases
GABA neurotransmitter release in brain slices from different brain
areas (Guyon et al., 2006;Heinisch andKirby,2010). Finally, agents
acting on GABA receptors including GABA itself and GABAB
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receptors agonists/antagonists have been shown to reduce the
effect induced by the activation of the CXCR4 receptor on calcium
currents in brain slices of substantia nigra (Guyon et al., 2013).
PUTATIVE MECHANISMS OF INTERACTION (Figure 1)
INTERACTIONS BETWEEN RECEPTORS
Although CXCR4 is also functional as a monomer (Paavola et al.,
1998; Veldkamp et al., 2008, 2009), it has been shown to homo-
dimerize following CXCL12 interaction, a homo-dimerization
which is necessary for its functionality and signaling (Mellado
et al., 2001; Toth et al., 2004), and is accompanied by receptor
phosphorylation as well as changes in signal transduction pro-
cesses (Rodriguez-Frade et al., 2001). This enables the activation
of the JAK/STAT pathway which allows the subsequent triggering
of G-protein dependent signaling events (Vila-Coro et al., 1999).
CXCR4 can also form heterodimers with other GPCRs. For
example, CXCR4 has been shown to form heterodimers with
CXCR7, CCR2, and CCR5 and delta opioid receptors (Percher-
ancier et al., 2005; Pello et al., 2008; Levoye et al., 2009; Sohy et al.,
2009). It is therefore tempting to imagine that CXCR4 could
form heterodimers with GABAB receptors, which could explain
the functional interactions that have been observed. However,
although this has not been investigated in mammalian cell mem-
branes, by co-expressing GABAB receptors tagged with Td tomato
(red ﬂuorophore) and CXCR4 receptors tagged with GFP (green)
in the membrane of Xenopus oocytes, data obtained using TIRF
FIGURE 1 | Putative crosstalk between CXCL12-CXCR4/CXCR7 and
GABAergic systems.The chemokine CXCL12 can act on its receptors CXCR4
and CXCR7, activating several intracellular pathways. At the pre-synaptic level,
CXCR4 stimulation increases the pre-synaptic release of neurotransmitter
such as GABA (opposite to GABAB receptors stimulation). CXCL12 receptors
and GABAB receptors could interact at different levels including the receptors
themselves (by heteromerization), the G-proteins they activate, their common
target channels (G-protein activated inward rectiﬁer potassium channels and
voltage-activated calcium channels) or the second messenger cascades. In
addition, GABA is a negative allosteric modulator of CXCR4 receptors, which
could contribute to the negative feedback of GABA on its presynaptic release.
Black and green arrows: activation; red lines: inhibition.
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microscopy showed that CXCR4 and GABAB receptors did not
co-localize in themembrane (Guyon et al., 2013), thus it is unlikely
that these two GPCR receptors form heterodimers.
CROSSTALK AT THE LEVEL OF SECOND MESSENGER CASCADES
CXCR4 and GABAB receptors are both GPCR activating GIRK,
and modulating voltage-gated channels such as K channels Kv2.1
and HVA Ca2+ currents (Guyon and Nahon, 2007; Shepherd
et al., 2012), GABAB receptors stimulation decreasing HVA Ca2+
currents (Guyon and Leresche, 1995) while CXCR4 stimulation
potentiating them (Guyon et al., 2008). Therefore, it is likely that
the two systems might interfere at the level of the G protein, the
secondmessenger cascade and/or the target channel in their action
on neuronal excitability.
DIRECT PHARMACOLOGICAL ACTION
While somewhat unexpected, GABA and the agonists/antagonists
of GABAB receptors (i.e., baclofen and the antagonists CGP55845
and 54626) were recently found to act pharmacologically directly
on CXCR4 in an allosteric manner. Using electrophysiology in
Xenopus oocytes and human embryonic kidney (HEK293) cells
in which Rat CXCR4 and the GIRK channel were co-expressed, it
could be demonstrated that GABAB antagonist and agonist mod-
ify the CXCL12-evoked activation of GIRK channels (Guyon et al.,
2013). By expressing CXCR4 receptors in heterologous systems
lacking GABAB receptors and performing competition binding
experiments it could be investigated whether GABAB ligands bind
to CXCR4. Electrophysiology data and FRET experiments sug-
gested that GABAB ligands do not bind CXCR4 at the CXCL12
binding pocket suggesting allosteric modulation (Guyon et al.,
2013). Finally, backscattering interferometry (BSI) on lipopar-
ticles containing only the CXCR4 receptor allowed to quantify
the CXCR4 binding afﬁnities for the GABAB ligands (including
GABA), which were in a similar range to the afﬁnities of the lig-
ands for GABAB receptors themselves, thus conﬁrming that GABA
andGABAB receptor ligands directly interact allostericallywith the
CXCR4 receptor (Guyon et al., 2013). In the future, it will be of
interest to search for putative effects of GABAandGABAB receptor
ligands on CXCR7.
PHYSIOLOGICAL CONSEQUENCES
There are many pathways by which GABA and CXCL12 systems
can interact. GABA is able to block the effect of CXCL12 on
CXCR4. Thus, it is likely that when the GABAergic system is
activated, GABA released in the brain will antagonize the effect
of CXCL12 on its receptor CXCR4, and thus could inﬂuence
the chemokine neurotransmission as well as the inﬂammatory
response in the central nervous system. Conversely, it has pre-
viously been shown that CXCR4 stimulation by CXCL12 can
increase GABA release (Guyon and Nahon, 2007; Bhattacharyya
et al., 2008; Qu et al., 2008). Therefore, there is reciprocal cross talk
between these two systems that may affect several physiological
levels.
NEUROTRANSMISSION
CXCR4 activation by CXCL12 has been shown to increase presy-
naptic neurotransmitter release and particularly GABA release in
several neuronal populations (Guyon and Nahon, 2007; Bhat-
tacharyya et al., 2008; Qu et al., 2008). If GABA can in turn block
the effects of CXCL12, this could represent a negative feedback
loop for presynaptic chemokine release (Guyon and Nahon, 2007;
Bhattacharyya et al., 2008; Qu et al., 2008). Indeed, when applying
CXCL12 for several minutes, a transient increase in the frequency
of sPSCs is frequently observed, followed by a reduced activity (see
Figure 3 in Guyon et al., 2006). This reduction could be due to an
antagonistic effect of GABA, although desensitization of CXCR4
itself cannot be excluded.
In dopaminergic neurons of the rat substantia nigra, CXCR4
stimulation byCXCL12 induces an increase of release of presynap-
tic neurotransmitter, particularly of GABA (Guyon et al., 2006).
CGP55845A (500 nM) blocks the outward GIRK current induced
by CXCL12 (recorded in the presence of glutamate receptor block-
ers), which was ﬁrst interpreted as an effect mediated through
GABAB receptor stimulation by GABA spilling over following
CXCL12 presynaptic stimulation and increase in GABAB release.
However, GIRK currents might have been activated by the stimu-
lation of postsynaptic CXCR4 byCXCL12,whichwas then blocked
by CGP55845A.
INFLAMMATORY RESPONSE
Expression of GABAB receptors on cells of the immune system has
recently been described, as well as a possible link to the inﬂam-
matory response (Tian et al., 2004; Rane et al., 2005). Along this
line, it has been shown that baclofen, a selective GABAB recep-
tor agonist, reduces chemotaxis from human mononuclear cells
towardCXCL12 (Duthey et al., 2010). Given that humanmononu-
clear cells express both GABAB and CXCR4 receptors, the ﬁnding
that an agonist of one receptor alters the response to an agonist
of the other receptor was interpreted to indicate a heterologous
desensitization between chemokine and GABAB receptors. This
observation along with our own observations on the chemotaxis
of cancer cell lines expressing CXCR4 can also be reinterpreted as
a direct allosteric action of baclofen on CXCR4.
PUTATIVE APPLICATIONS IN CANCER TREATMENT
Baclofen treatment was demonstrated to reduce the incidence of
some carcinogen-induced gastrointestinal cancers in rats (Tatsuta
et al., 1990) as well as human hepatocarcinoma cell growth (Wang
et al., 2008). By contrast, baclofen promotes human prostate
cancer cell migration (Azuma et al., 2003).
Similarly, it has been shown thatGABA can affect the cell prolif-
eration and have anti-inﬂammatory properties through inhibition
of ﬁbroblast proliferation, although the mechanism of action of
GABA was not elucidated (Han et al., 2007). We suggest that
GABA could have acted through the CXCR4 receptor, as CXCR4
is expressed on ﬁbroblasts (Qu et al., 2008).
HIV INFECTION
Fusion of HIV-1 with the host cell membrane is initiated by the
binding of the viral envelope glycoprotein gp120 to both the CD4
cell surface receptor and one of the CXCR4 or CCR5 chemokine
receptors (Doranz et al., 1997; Gabuzda and Wang, 2000). It has
therefore been suggested that the CXCR4-CXCL12 axis may be
an important therapeutic target for prevention of HIV infection.
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It will therefore be of interest to test the aptitude of baclofen
and other GABAB receptor agents to affect the CXCR4–GP-120
interaction.
As a conclusion, agents interacting at CXCR4 could be use-
ful to treat cancer as well as HIV infection. Baclofen is currently
approved for the treatment of spasticity in patients with spinal
cord injury, cerebral palsy, traumatic brain injury, multiple scle-
rosis and other disorders (Plassat et al., 2004; Guglani and Lodha,
2007; Kolaski and Logan, 2008; Rekand and Gronning, 2011).
Recently, it has been used in the treatment of alcohol dependence
and withdrawal (Addolorato et al., 2006). The allosteric effects of
baclofen on CXCR4 could contribute to its beneﬁcial effects as
CXCR4 often co-localizes with GABAB receptors. At the opposite,
it could be responsible for its side effects. Overall, the effect of
GABAergic agents on CXCR4 suggests new therapeutic potentials
for neurological and immune diseases.
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